Abstract:Background It is estimated that up to 5% of inflammatory bowel disease (IBD) patients have clinically significant liver disease due to multifactorial causes such as underlying Primary Sclerosing Cholangitis, pharmacotherapy, fatty liver disease or nodular regenerative hyperplasia. In recent years, transient elastography (TE), which uses the sonic detection of liver stiffness to predict hepatic fibrosis has increasingly replaced the need for a liver biopsy. It has been validated in patients with chronic hepatitis C as an accurate non-invasive predictor of advance fi brosis and cirrhosis. Aims Our aim was to evaluate the prevalence of clinically significant liver disease in IBD patients as defi ned by an increased liver stiffness measurement (LSM) using Transient Elastography (FibroScan®). Methods 110 random IBD patients and 55 non-IBD control patients (composed of patient relatives and hospital staff) had their LSM recorded. The median reading in kilopascals (kPa) of 10 successful acquisitions was recorded by a nurse trained in performing TE. Age, gender, body mass index (BMI), history of liver disease, presence of diabetes, number of cigarettes smoked and standard drinks of alcohol consumed per week, were recorded and entered as covariates in multivariate analysis. Results Of the 110 IBD patients, 71 (64.5%) had Crohn’s disease. There were no significant differences in mean age (43 ± 15 yrs vs. 41 ± 17 yrs), gender (males, 47% vs. 51%) and number of standard alcoholic drinks consumed per week (6 ± 9 vs. 4 ± 7) between IBD patients and non-IBD controls respectively (P > 0.05). IBD patients smoked significantly more cigarettes per week compared to non-IBD controls (15 ± 42 vs. 1 ± 6, P = 0.001). Four IBD patients had diabetes compared to none in the non-IBD group. Seven patients in the IBD group (6.4%) had an LSM reading of greater than 8 kPa compared to none in non-IBD control group. One patient, had an LSM of 14.9 kPa, normal liver function tests and evidence of portal hypertension on ultrasound. Although the overall LSM in the IBD group was higher, there was no statistical difference between the mean LSM reading of IBD patients (5.2 ± 2.5 kPa) and non-IBD controls (4.8 ± 1.2 kPa) on univariate (P = 0.22) and multivariate (P = 0.67) analysis. IBD patients had a significantly higher BMI compared to non-IBD controls (26 ± 4.6 vs. 24 ± 3.3, P = 0.04) and this was the only independent predictor of a high LSM reading on multivariate analysis (P < 0.0001). Conclusion IBD patients are more likely to have a higher BMI compared to non-IBD subjects and this is the main reason for their higher LSM reading. This implies that non-alcoholic fatty liver disease may be a significant cause of occult liver disease in IBD patients and attention should be paid to optimise metabolic risk factors such as minimising corticosteroid use.

Liver Fibrosis Index-4 Does Not Correlate to Liver Elastography in Patients with Inflammatory Bowel Disease

Degree of Discordance Between FIB-4 and Transient Elastography: An Application of Current Guidelines on General Population Cohort

P1178 Detection of occult liver disease in patients with Inflammatory Bowel Disease

NAFLD, the changing face of IBD

Fibrofast and Fibrosis-4 versus Fibroscan as Indicators of Hepatic Fibrosis in Non Alcholic Fatty Liver Disease Patients: A Cross-Sectional Study

Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD

An elevated FIB-4 score is not associated with cardiovascular events: a longitudinal analysis from 137 842 patients with and without chronic liver disease

Comparative evaluation of APRI, FIB-4, HFS, and NFS: Scoring tools for liver fibrosis in a Mexican population with MASLD

The role of fibrosis index FIB-4 in predicting liver fibrosis stage and clinical prognosis: A diagnostic or screening tool?

FIB-4 Reliability in Patients With Severe Obesity: Lower Cutoffs Needed?

An Elevated FIB-4 Score is associated with the severity of heart failure

Effect of liver inflammation on accuracy of FibroScan device in assessing liver fibrosis stage in patients with chronic hepatitis B virus infection

Fibrosis-4 score for screening of metabolic dysfunction-associated steatotic liver disease (MASLD): Data from a population-based sample in Tuscany

FIB-4 and Severe Liver Disease Outcomes in Primary Care: A Stratified Cox Analysis

FIB-4 Index and Liver Stiffness Measurement are Potential Predictors of Atherosclerosis in Metabolic Dysfunction-Associated Steatotic Liver Disease

The FIB-4 Index Predicts the Development of Liver-Related Events, Extrahepatic Cancers, and Coronary Vascular Disease in Patients with NAFLD

S1935 How Accurate Is FIB-4 vs Fibroscan in Clinical Practice: Comparing Methodology of Liver Fibrosis Assessment

S1703 The Role of Fibroscan in Assessment of Liver Fibrosis in Patients With Diabetes Mellitus and Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD)

Predictive Performance of Elift for Liver Inflammation and Fibrosis in Chronic Liver Diseases

A direct comparison of non-invasive blood markers of liver fibrosis as associates of cardiovascular risk. The Athens cardiometabolic registry

P298 Risk factors for the progression of non-alcoholic fatty liver disease in people with inflammatory bowel disease